|MDACC Study No:||2012-0573 (clinicaltrials.gov NCT No: NCT01568866)|
|Title:||A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma|
|Principal Investigator:||Michael Wang|
|Treatment Agent:||Bortezomib; Carfilzomib; Dexamethasone|
|Study Description:||The goal of this clinical research study is to compare the combination of |
carfilzomib and dexamethasone to the combination of bortezomib (Velcade®) and
dexamethasone in patients with relapsed MM.
Carfilzomib is designed to block cancer cells from repairing themselves. If
the cancer cells cannot repair themselves, this may cause them to die.
Velcade is designed to block a protein that causes cells to grow. This may
cause cancer cells to die.
Dexamethasone is a corticosteroid that is similar to a natural hormone made by
your body. Dexamethasone is often given to MM patients in combination with
other therapy to treat cancer.